Discussing Tavapadon?
Tavapadon has been studied in adults with early Parkinson’s as a starting option and in those with more advanced disease as an add-on to existing therapy. Because it is designed for once-daily use, it could appeal to people seeking simpler routines or those experiencing motor fluctuations.
Keep in mind that tavapadon is not yet approved by the FDA as of the latest updates. AbbVie submitted a New Drug Application in 2025, supported by the TEMPO program data. Review processes typically take several months, so timelines for availability depend